Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials

July 16, 2024 10:00 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

SHANGHAI, July 16, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963, hereinafter referred to as "Huadong Medicine"). The jointly developed ADC drug, designated as project number SYHD001, has successfully entered Phase I clinical trials. This important milestone not only signifies substantial progress in the collaboration between the two parties but also serves as a powerful testimony to the cutting-edge technology platform of Sanyou Bio.

SYHD001, as an ADC drug, presents extremely high technical demands and development complexities. Sanyou Bio has laid a solid foundation for the successful development of the drug from the outset with its three innovative platforms for biologic drugs: Super-trillion molecule discovery platform, Integrated R&D platform, and Intelligent R&D platform. Sanyou Bio completed the target research, raw material preparation, key molecule generation, assisted and cooperated in completing ADC conjugation and some in vitro and in vivo efficacy experiments, and helped the client to quickly and efficiently screen out compliant, high-expression, high-quality, and highly stable industrial cell lines for the project, thereby ensuring high-quality production and supply of ADC drugs and successfully promoting the project to rapidly complete IND filing and enter Phase I clinical trials.

Dr. Guojun LANG, CEO of Sanyou Bio, said "We are extremely honoured to collaborate with such an excellent partner as Huadong Medicine to advance SYHD001 to the clinical stage. In the future development, Sanyou Bio will continue to be committed to technological innovation and constantly enhance the core competitiveness of our own technology platform. We look forward to partnering with more collaborators to jointly promote the development of the biopharmaceutical industry and contribute more to the cause of human health."

Since its establishment in 2015, Sanyou Bio has provided systematic solutions from target to IND to accelerate the drug development process through five key categories of innovative biologic drug R&D. The five key R&D stage services include: Target Discovery and Raw Material Preparation, Molecule Generation, Molecule Optimization, Pharmacology and Efficacy Analysis, and Cell line Development and Production Process.

To date, Sanyou Bio has served 1,000+ pharmaceutical clients, 7 CPO projects have been obtained IND approval, 10+ projects are in the preclinical R&D stage, 26 collaborative R&D projects are progressing in manner. It has extensive experiences covering 100+ PCC projects and 300+ antibody drug discovery projects, and has cooperated or assisted partners in publishing more than 50 papers, including top journals such as CNS.

About Huadong Medicine

Huadong Medicine Co., Ltd. (SZ.000963) was founded in 1993, with its headquarters located in Hangzhou, Zhejiang. Adhering to the company value of "Science Driven, Patient Centered", Huadong Medicine has gone through over 20 years of development, and has established a business presence covering the entire pharmaceutical industry chain, with four major business segments: pharmaceutical industry, pharmaceutical commerce, aesthetic medicine, and industrial microorganism, and has grown into a large comprehensive pharmaceutical listed company that integrates pharmaceutical R&D, manufacturing, and distribution. In 2022, Huadong Medicine achieved a revenue of 37.715 billion yuan. With a current employee count exceeding ten thousand, the company possesses extensive commercial coverage and strong marketing capabilities.

About Sanyou Bio

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make the R&D easy for innovative biologics".

Sanyou has established an integrated innovative biologic drug R&D laboratory with advanced facilities, and has a professional team with the majority holding a Ph.D. or master degree. Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence", which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform, and supported by platforms of material preparation, biologics discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc.

Sanyou's business network has expanded to all parts of the world, including Asia, US and Europe, and established branches in Boston, Philadelphia, San Diego and London. Sanyou has established friendly business relationships with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Sanyou received National-level certification as a high-tech enterprise and a Specialized and Sophisticated enterprise, and passed the ISO9001 quality assurance certification and GB/T intellectual property management system certification.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.